Morgan Stanley lowered the firm’s price target on Accelerant (ARX) to $17 from $18 and keeps an Equal Weight rating on the shares. The firm updated models in the insurance space post the Q3 reports. For property and casualty, Morgan Stanley sees a softening cycle heading into 2026, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARX:
- Tiger Global buys Netflix, exits Eli Lilly in Q3
- Accelerant price target lowered to $15 from $18 at Piper Sandler
- Accelerant Holdings Reports Significant Loss Amid Revenue Growth
- Accelerant Holdings Class A: Strong Performance and Promising Growth Prospects Drive Buy Rating
- Accelerant reports Q3 adjusted EPS 38c, consensus 21c